Background
==========

Microtubules are involved in a diverse range of cellular functions, including motility, maintenance of cell shape, adhesion, intracellular trafficking of macromolecules and organelles, and, most importantly, mitosis \[[@B1]-[@B4]\]. The role that microtubules play in mitosis makes them one of the most highly validated targets for the development of chemotherapeutic drugs against rapidly dividing cancer cells \[[@B5]\]. Evidence has shown that subtle alteration in the structure of microtubules can cause improper attachment of chromosomes and impair the tension, which in turn signals the spindle checkpoint to prevent anaphase onset and chromosome segregation. The cell eventually exits mitosis aberrantly and undergoes apoptosis \[[@B5]\]. The effectiveness of microtubule-targeting drugs has been demonstrated by the extensive clinical use of several vinca alkaloids (vinblastine, vincristine, etc.) and taxanes (paclitaxel and docetaxel) for the treatment of a wide variety of human cancers \[[@B5]\]. Cancer cells treated with these agents are characterized by cell cycle arrest at G~2~/M phase. Microtubule-targeting drugs are, therefore, frequently referred to as antimitotic agents.

Structurally, microtubules are composed of similar 50 kDa α/β-tubulin heterodimers that share 40% sequence identity with almost identical three-dimensional structures \[[@B6]\]. Formation of microtubules involves reversible, noncovalent polymerization of repeating α/β-tubulin subunits that bind head to tail into protofilaments \[[@B7]-[@B9]\]. Tubulins are rich in thiol groups with a total of 20 free thiol groups per tubulin dimer (12 in α-tubulin and 8 in β-tubulin) \[[@B10],[@B11]\]. These thiol groups are critical to tubulin polymerization or microtubule formation and function \[[@B12]\]. Loss of these thiol groups inevitably affects tubulin polymerization as observed in the oxidation \[[@B13],[@B14]\] or alkylation \[[@B11]\] of these thiol groups. Mechanistically, most current antimitotic agents are classified into one of three classes based on their interactions with microtubules \[[@B15]\]. The first class of antimitotic agents, exemplified by paclitaxel, interact with the taxane binding site (M-loop) and cause microtubule stabilization \[[@B15]\]. The second class includes the vinca alkaloids which inhibit tubulin assembly by interacting at the interface between α,β-dimers resulting in microtubule depolymerization. The third class of compounds interact at the colchicine-binding site, the interface of the α,β-dimers, and prevent assembly of tubulin into microtubules \[[@B15]\].

In our earlier study with 2-acetylamino-3-4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino)phenylcarbamoylsulfanyl\]propionic acid (2-AAPA, Figure [1](#F1){ref-type="fig"}) to modulate intracellular thiol oxidative stress, we found that 2-AAPA caused cell morphological change and cell detachment indicating that the cellular cytoskeletal structure was affected \[[@B16],[@B17]\]. Further, 2-AAPA was shown to induce protein *S*-glutathionylation \[[@B16],[@B17]\]. Protein *S*-glutathionylation is a process where a glutathione molecule (GSH) is connected to a protein thiol (PSH) through a disulfide bond (-S-S-) (Scheme [1](#C1){ref-type="fig"}) \[[@B13],[@B18],[@B19]\]. In view of the critical role thiol groups play in microtubule function and the rich content of thiol groups present in the microtubule structure, we suspected that 2-AAPA might induce microtubule *S*-glutathionylation and the *S*-glutathionylation might cause dysfunction of microtubules. If confirmed, microtubule *S-*glutathionylation could be a novel approach for the development of antimitotic agents which exhibit a different mechanism of action than the currently employed antimitotic drugs. These agents will be helpful in overcoming the emerging drug resistance problem associated with vinca alkaloids and taxanes. The aim of this study was to investigate whether microtubule can be *S*-glutathionylated in cancer cells and whether the *S*-glutathionylation leads to microtubule dysfunction and cell growth inhibition.

![Chemical structure of 2-AAPA.](1471-2407-12-245-1){#F1}

![Protein S-glutathionylation.](1471-2407-12-245-i1){#C1}

Methods
=======

Materials and cell lines
------------------------

2-AAPA was synthesized as described previously \[[@B20]\]. 2-AAPA is currently also available from Sigma-Aldrich Chemical Co. (Milwaukee, WI). *p*-\[3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide\] (MTT), ethylenediaminetetraacetic acid (EDTA), *N*-2-hydroxyethylpiperazine-*N*'-2-ethanesulfonic acid (HEPES), 2-amino-2-(hydroxymethyl)propane-1,3-diol hydrochloride (Tris--HCl) buffer, 4′,6-diamidino-2-phenylindole (DAPI), paclitaxel, vinblastine, propidium iodide (PI), RNase, horseradish peroxidase, sodium dodecyl sulfate (SDS), Triton-X-100, and mouse monoclonal anti-α-tubulin-FITC were obtained from Sigma-Aldrich Chemical Co. (Milwaukee, WI). The Vybrant™ Apoptosis Assay Kit \#2 was purchased from Molecular Probes (Carlsbad, CA). Dulbecco's phosphate buffered saline (DPBS), fetal bovine serum (FBS), minimum essential medium (MEM), phosphate buffered saline (PBS), RPMI-1640, and trypsin-EDTA were from Mediatech, Inc. (Herndon, VA). Dulbecco's modified eagle's medium (DMEM) was purchased from the American Type Culture Collection (ATCC). Sulfosalicylic acid was purchased from J.T. Baker Chemical Co. (Phillipsburg, NJ). Antibodies of α-tubulin and β-tubulin, secondary antibodies and GST-agarose beads were from Santa Cruz Biotechnology (Santa Cruz, CA). ECL Plus Kit was purchased from Amersham Biosciences (Piscataway, NJ). Other reagents were obtained in their highest purity grade available commercially. Cells were cultured in MEM, DMEM or RPMI 1640 growth medium supplemented with 10% FBS, 100 units/mL of penicillin (Mediatech, Inc., Herndon, VA) and 100 μg/mL of streptomycin (Mediatech, Inc., Herndon, VA) in a humidified atmosphere containing 5% CO~2~ at 37°C. Human cancer cell lines NCI/ADR-RES (ovarian cancer), OVCAR-3 (ovarian cancer), UACC-62 (melanoma), NCI-H226 (lung cancer), PC-3 (prostate cancer), and UO-31 (renal carcinoma) were obtained from the National Cancer Institute (NCI); A-431 (epidermoid carcinoma), SK-MEL-2 (melanoma), and MCF7 (breast cancer) were obtained from ATCC. GC~3~/c1 human colon adenocarcinoma cells were kindly provided by Dr. Peter J. Houghton of St. Jude Children's Research Hospital, Memphis, Tennessee.

*In vitro* cytotoxicity evaluation
----------------------------------

2-AAPA was tested *in vitro* for cytotoxicity against NCI/ADR-RES, OVCAR-3, UACC-62, UO-31, NCI-H226, A431, MCF7, PC-3, SK-MEL-2 and GC~3~/c1 cells in 96-well plates using MTT assay to determine IC~50~ values. In brief, exponentially growing cells were plated in 96-well plates (1500, 2000, 1500, 2000, 1800, 1000, 2500, 2000, 2000 and 5000 cells/well for NCI/ADR-RES, OVCAR-3, UACC-62, UO-31, NCI-H226, A431, MCF7, PC-3, SK-MEL-2 and GC~3~/c1 cells respectively) in various media (RPMI 1640 for NCI/ADR-RES, OVCAR-3, UACC-62, UO-31, NCI-H226, PC-3, SK-MEL-2 and GC~3~/c1, MEM supplemented with 10 μg/mL insulin for MCF7, and DMEM for A431 respectively). The cells were allowed to attach at 37°C in a humidified atmosphere of 5% CO~2~ for 24 h, and then the medium was replaced with the medium containing various concentrations of 2-AAPA. Cells were exposed to the medium containing 2-AAPA for 6 days at the same incubation condition. After the treatment, MTT assay was performed to determine IC~50~ values.

Determination of protein *S*-glutathionylation by HPLC
------------------------------------------------------

Protein samples from UACC-62 cells treated with 2-AAPA were prepared and *S*-glutathionylation was determined by the HPLC method described by Chen et al. \[[@B16]\].

Determination of tubulin *S*-glutathionylation by a pull-down assay
-------------------------------------------------------------------

Protein was extracted from UACC-62 cells using the method described by Chen et al. \[[@B16]\] with minor modification. Briefly, UACC-62 cells (5 million) were detached by trypsinization and treated with 100 μM 2-AAPA at 37^o^C for 20 min. After washing with ice-cold PBS, one milliliter of ice-cold sulfosalicylic acid aqueous solution (3%, w/w) was added to the cells. The lysed cells were centrifuged at 15000 × *g* for 1 min. The supernatant was discarded and the lysate pellets were washed thoroughly with the sulfosalicylic acid aqueous solution (1 mL × 3) to ensure that no residual non-protein thiols were left. Then the pellets were washed twice with Tris--HCl buffer (50 mM, pH 7.4) containing 5 mM EDTA. The pellets were collected by centrifugation at 15000 × *g* for 1 min and solubilized in 200 μL of denaturing lysis buffer with 1% SDS without dithiothreitol prepared as described by Bonifacino et al. \[[@B21]\]. The protein solution was then heated at 100°C for 5 min. The supernatant was collected after centrifugation at 15000 × *g* for 5 min and stored at −20°C for future use. For tubulin *S-*glutathionylation determination, 500 μg of protein sample was incubated with 40 μL of GST- agarose beads in a total of 1 mL of HEPES buffer containing 1% Triton X-100 overnight at 4°C on a platform rocker. GST-agarose beads were collected by centrifugation at 5,000 × *g* for 5 min at 4°C and gently washed with PBS followed by centrifugation to collect the beads. The wash was repeated four times. After the final wash, supernatant was carefully aspirated and discarded, and pellets were resuspended in 60 μL of 2× non-reducing electrophoresis sample buffer. Samples were boiled for 5 min at 100°C and centrifuged at 15000 × *g* at 4°C for 5 min. The *S*-glutathionylated tubulin proteins in the supernatant were subjected to SDS- PAGE. Then the proteins in gels were transferred to nitrocellulose membranes and probed with the appropriate dilution of primary α- or β-tubulin antibodies followed by appropriate horseradish peroxidase (HRP) conjugated secondary antibody and ECL Plus detection kit. The bands were visualized using a UVP Biochem Gel Documentation system (UVP, Inc., Upland, CA).

Cell morphological change
-------------------------

Cultured UACC-62 cells were treated with 50 μM 2-AAPA at 37^o^C. Live cell images were taken by a Zeiss AXIO Observer A1 microscope equipped with a temperature-controlled stage at 37°C.

Indirect immunofluorescence microscopy
--------------------------------------

UACC-62 cells were incubated with 2-AAPA at 37°C in a humidified atmosphere of 5% CO~2~ for various time periods and then fixed in 4% paraformaldehyde at room temperature for 1 h. The cells were washed thrice with PBS and incubated with cell permeable solution (0.1% Na-citrate, 0.1% Triton-X-100 in 1 × PBS) at room temperature for 1 h. After incubation with the blocking solution (PBS containing 5% bovine serum albumin) overnight at 4°C, microtubules were visualized using a mouse monoclonal anti-α-tubulin-FITC (1:1,000), and nuclei were stained with DAPI (1 μg/mL). Fluorescent images were taken with an Olympus AX70 fluorescence microscope. Paclitaxel and vinblastine were employed as positive controls for microtubule stabilization and microtubule depolymerization, respectively.

Analysis of cellular DNA content by flow cytometry
--------------------------------------------------

UACC-62 cells (1 million) were plated in 100 mm culture dishes in RPMI 1640 medium for 24 h attachment at 37^o^C in a humidified atmosphere of 5% CO~2~, and then treated with 15 mL of RPMI 1640 medium containing various concentrations of 2-AAPA for 12 h or 24 h at the same incubation condition. At the end of treatment, adherent cells were harvested and washed twice with ice-cold PBS. One million cells of each sample were fixed with 70% ethanol in DPBS at 4°C. The fixed cells were then centrifuged (700 × g, 5 min) and washed with staining buffer. After the wash, the samples were centrifuged (700 × g, 5 min), and the pellets were treated with 100 μL of RNase A (1 mg/mL) for 30 min at 37°C. After incubation, 900 μL of staining buffer was added to the samples to bring the volume to 1 mL followed by addition of 20 μL of propidium iodide (PI) (1 mg/mL). The sample was then incubated in the dark at room temperature for 30 min before being analyzed with a BD FACScan™ flow cytometer (BD Biosciences, San Jose, CA) using CellQuest Software (BD Biosciences, San Jose, CA).

Apoptosis assay by flow cytometry
---------------------------------

UACC-62 cells (0.2 million) were plated in 25 cm^2^ flasks with RPMI 1640 growth medium. After a 24 h-attachment at 37^o^C in a humidified atmosphere of 5% CO~2~, UACC-62 cells were treated with RPMI 1640 growth medium containing various concentrations of 2-AAPA. Annexin V/PI staining was performed using the Vybrant™ Apoptosis Assay Kit \#2 according to the manufacture's instruction. The samples were analyzed with a BD FACScan flow cytometer.

Statistical analysis
--------------------

Data were analyzed with INSTAT software (Graph Pad, San Diego, CA). ANOVA followed by Tukey's post test was applied to compare the statistical difference between 2-AAPA treatment groups and untreated controls. Significance in all experiments was considered at *P* \< 0.05. Values were expressed as mean ± the standard deviation of the mean.

Results
=======

*In vitro* cytotoxicity of 2-AAPA against various human cancer cells
--------------------------------------------------------------------

The cell growth inhibition of 2-AAPA was evaluated with various human cancer cell lines. As demonstrated in Table [1](#T1){ref-type="table"}, 2-AAPA exhibited similar IC~50~ values, in the range of 22 to 75 μM, against all the tested cancer cells revealing that the cytotoxicity is not cancer cell type-dependent. Based on the IC~50~ values, UACC-62 appears to be the most sensitive cells towards 2-AAPA and, therefore, was selected for further study.

###### 

Anticancer activity evaluation of 2-AAPA against various human cancer cells

  **Cell line**                  **IC50**^**\***^**(μM)**
  ------------------------------ --------------------------
  NCI/ADR-RES (ovarian cancer)   28 ± 1
  OVCAR-3 (ovarian cancer)       33 ± 2
  UACC-62 (melanoma)             22 ± 1
  SK-MEL-2 (melanoma)            40 ± 9
  NCI-H226 (lung cancer)         68 ± 4
  UO-31 (kidney cancer)          44 ± 10
  A431 (skin cancer)             73 ± 4
  PC-3 (prostate cancer)         50 ± 12
  MCF7 (breast cancer)           75 ± 5
  GC~3~/c1 (colon cancer)        42 ± 1

^*\**^IC~50~: concentration of a drug required to reduce cell growth by 50%. Cells were treated with 2-AAPA for 6 days. Cell survival rates were determined by the MTT assay. IC~50~ values were derived from corresponding dose--response curves. The data are presented as the mean ± SD of three independent experiments.

Protein *S*-glutathionylation induced by 2-AAPA
-----------------------------------------------

Previously, protein *S*-glutathionylation was detected in both CV-1 (monkey kidney cells) and OVCAR-3 cells treated with 100 μM 2-AAPA \[[@B16],[@B17]\]. Before checking whether microtubules were *S*-glutathionylated in UACC-62 cells, we first determined whether proteins were *S*-glutathionylated in the presence of 2-AAPA. UACC-62 cells were treated with 100 μM 2-AAPA for 20 min and protein *S*-glutathionylation was determined as reported \[[@B16]\]. Protein *S*-glutathionylation (2.19 ± 0.30 nmol GSH/million cells) was detected in UACC-62 cells. The amount of protein *S*-glutathionylation by 2-AAPA induced in UACC-62 cells was similar to that obtained from OVCAR-3 cells confirming 2-AAPA's ability to induce cellular protein *S*-glutathionylation. UACC-62 cells were then treated with 50 μM 2-AAPA, a concentration close to the IC~50~ value, to determine the time profile of protein *S-*glutathionylation. The results are presented in Figure [2](#F2){ref-type="fig"}. Protein *S*-glutathionylation was observed at 5 min and reached the maximum in 10 min. At 1 h, protein *S-*glutathionylation was found to be about 40% of the maximum and continued to fall afterwards (Figure [2](#F2){ref-type="fig"}).

![**2-AAPA induces protein*S*-glutationylation in UACC-62 cells.** UACC-62 cells were treated with 50 μM 2-AAPA for different time periods and protein *S*-glutathionylation was determined by the HPLC method described by Chen et al. \[[@B16]\]. The results were presented as the mean ± SD of triplet determination of one set of samples. No protein *S*-glutathionylation was detected in untreated cells. Control 1 and control 2 were conducted at 5 min and 4 h respectively. No *S*-glutathionylation was detected in both control 1 and control 2.](1471-2407-12-245-2){#F2}

Determination of microtubule *S-*glutathionylation
--------------------------------------------------

Due to the quantity limitation of microtubules in cells, our HPLC method for protein *S-*glutathionylation was not sensitive enough to detect microtubule *S*-glutathionylation. Microtubule *S*-glutathionylation was thus investigated by a pull-down assay reported by Cheng and co-workers \[[@B22]\] with modification.

Cheng and co-workers used biotinylated glutathione *S*-transferase (GST) from *Schistosoma japonicum* to detect the glutathione moiety of *S-*glutathionylated protein. Since biotinylated GST was not commercially available, we decided to use GST-agarose beads containing the GST from the same species as an alternative. *S*-Glutathionylated proteins were pulled down by GST-agarose beads followed by the Western blot analysis with the antibodies of α-tubulin and β-tubulin. Figure [3](#F3){ref-type="fig"} shows that both α-tubulin and β-tubulin were *S*-glutathionylated when UACC-62 cells were treated with 100 μM 2-AAPA for 20 min while no *S*- glutathionylated tubulins were detected in the controls. The densities of the bands are consistent with the fact that α-tubulin has more thiol groups than β-tubulin.

![**2-AAPA induces tubulin*S*-glutathionylation.** UACC-62 cells were treated with 100 μM 2-AAPA for 20 min and *S*-glutathionylated proteins were captured by a pull-down assay using GST-agarose beads followed by Western blot analysis. α- and β-Tubulins were detected as described in the method.](1471-2407-12-245-3){#F3}

Effects on microtubule structure
--------------------------------

To confirm that microtubule structure was affected by the *S-*glutathionylation, the microtubule network was examined *via* immunofluorescence microscopy. As shown in Figure [4a](#F4){ref-type="fig"}, microtubules formed an intact network with fine mesh and filaments in untreated cells, while a significant reduction of microtubule density was observed in 2-AAPA-treated cells. Microtubules in treated cells were found dispersed and lost their original linear filamentous structure with disorganized central networks. To compare the effects with that of vinblastine, a microtubule depolymerizing antimitotic drug, and that of paclitaxel, a microtubule stabilizing antimitotic drug, the same experiments were conducted with vinblastine and paclitaxel. Figure [4a](#F4){ref-type="fig"} shows that the effect of 2-AAPA on microtubules was similar to that of vinblastine revealing that 2-AAPA depolymerized microtubules. The time-dependent effect of 2-AAPA on microtubule structure was further determined by treating UACC-62 cells with 50 μM 2-AAPA for different time periods (Figure [4b](#F4){ref-type="fig"}). Significant microtubule depolymerization was observed at 5 min. The deploymerization reached a maximum in 20 min. Recovery was observed at one hour. The time profile of microtubule depolymerization (Figure [4b](#F4){ref-type="fig"}) appears to match well with that of protein *S*-glutathionylation (Figure [2](#F2){ref-type="fig"}).

![**2-AAPA induces microtubule depolymerization in UACC-62 cells.** UACC-62 cells were treated with the indicated concentrations of 2-AAPA for 12 h (**a**), or with 50 μM 2-AAPA for indicated time periods (**b**), followed by fixation, permeabilization and indirect immunofluorescent analysis with an anti-α-tubulin-FITC. Nuclei were stained with DAPI. Paclitaxel and vinblastine were employed as positive controls for microtubule stabilization and microtubule depolymerization respectively. The data are derived from one of the three independent experiments.](1471-2407-12-245-4){#F4}

Cell morphological change
-------------------------

Consistent with the microtubule network being affected, the morphology of the cells was found to be changed. When UACC-62 cells were treated with 50 μM 2-AAPA, the morphology changes were observed as early as 6 min and involved more than 90% cells at the end of 20 min (Figure [5](#F5){ref-type="fig"}).

![**Effect of 2-AAPA on cell morphological changes in UACC-62 cells.** UACC-62 cells were treated with 50 μM 2-AAPA. Some of the cells undergoing morphological changes are marked by red arrows.](1471-2407-12-245-5){#F5}

Effects on the cell cycle
-------------------------

To further confirm microtubule function is being affected, the effect on the cell cycle was investigated. After being treated with 2-AAPA (35 and 50 μM), UACC-62 cells were found to be arrested in the G~2~/M phase (Figure [6](#F6){ref-type="fig"}) which is consistent with microtubule depolymerization.

![**Effect of 2-AAPA on cell cycle distribution in UACC-62 cells.** The histograms of UACC-62 cells treated with different concentrations of 2-AAPA for 24 h and 48 h are presented (**a**). The bar presentations reflects the quantification of cell cycle distribution at 24 h (**b**) and 48 h (**c**) respectively. Results are presented as the mean ± SD of three independent experiments. \*, *P* \< 0.05 indicates statistical significance in 2-AAPA treated groups as compared to the control.](1471-2407-12-245-6){#F6}

Effects on apoptosis
--------------------

All anti-microtubule agents identified to date are known to induce apoptotic cell death in cancer cells \[[@B23]\]. We evaluated the effect on apoptosis by treating UACC-62 cells with different concentrations of 2-AAPA for 12 h and 24 h (Figure [7](#F7){ref-type="fig"}). At 20 μM and 35 μM, 2-AAPA induced apoptosis in a dose- and time-dependent manner (*P* \<0.05).

![**Effect of 2-AAPA on the induction of apoptosis in UACC-62 cells.** UACC-62 cells were treated with different concentrations of 2-AAPA for 12 h and 24 h and stained with Annexin V and PI. Apoptotic cells were analyzed by flow cytometry (**a**). The percentages of apoptotic cells are presented for 12 h (**b**) and 24 h (**c**) treatment. Results are presented as the mean ± SD of three independent experiments. \*, *P* \< 0.05 indicates statistical significance in 2-AAPA treated groups as compared to the control.](1471-2407-12-245-7){#F7}

Discussion
==========

Antimitotic agents which induce tumor cell mitotic arrest and apoptosis are one of the most important classes of cancer chemotherapeutic agents \[[@B24]\]. However, the clinical application of the current antimitotic drugs is hampered by the problems of undesired side effects, poor pharmacokinetic properties, complex chemical structures, and emerging drug resistance \[[@B24]\]. The emerging drug resistance is of particular concern since it is the major cause of cancer treatment failure. Extensive efforts have been made to search for agents which can effectively interfere with microtubule function, especially those with a novel mechanism of action \[[@B25],[@B26]\].

In this study, we have demonstrated that microtubules can be *S-*glutathionylated. In view of the critical role of the thiol functional groups in microtubule polymerization, it is reasonable to suggest that the microtubule *S-*glutathionylation led to microtubule depolymerization. To confirm this, a correlation study between protein *S*-glutathionylation and microtubule depolymerization was conducted. Ideally, the correlation study should be conducted between microtubule *S*-glutathionylation and microtubule depolymerization. As indicated earlier, the analytical method for the quantification of protein *S*-glutathionylation is not sensitive enough to quantify microtubule *S*-glutathionylation. As presented in the result section, there was a clear correlation between protein *S-*glutathionylation and microtubule depolymerization. The time profile of microtubule depolymerization matched well with that of protein *S*-glutathionylation supporting that microtubule *S-*glutathionylation caused microtubule depolymerization. It is noted that protein *S-*glutathionylation increased initially in the first 10 min and then subsided after 20 min. Similar phenomena were observed earlier in CV-1 cells and believed to be a result of a recovered glutathione reductase activity \[[@B17]\]. The malfunction of microtubules was also reflected in the cell morphology and cell cycle distribution; cells were found to experience morphological changes, arrest at G~2~/M phase and undergo apoptosis.

Protein *S*-glutathionylation has been reported to be a reversible oxidative modification of PSH as a response of the cell to oxidative stress \[[@B27]-[@B31]\]. As indicated earlier, protein *S-*glutathionylation involves a mixed disulfide bond (P-S-S-G) formation between PSH and GSH. Once oxidative stress is over, the P-S-S-G will be reduced back to PSH enzymatically by glutaredoxin (Grx) \[[@B9],[@B27],[@B29],[@B32]-[@B34]\]. The rich thiol content of microtubules likely makes them susceptible to *S*-glutathionylation. Although the exact mechanism by which 2-AAPA produces protein *S*-glutathionylation, including microtubule *S*-glutathionylation, is not clear, our earlier data showed that protein *S*-glutathionylation induced by 2-AAPA correlates with the formation of the oxidized form of glutathione (GSSG) \[[@B35]\]. Consistently, Carletti and co-workers \[[@B36]\] recently reported that an increase in GSSG in neuron cells produced significant tubulin *S*-glutathionylation. They also determined that tubulin *S*-glutathionylation inhibited tubulin polymerization. Along the same line, we also found that an increase in intracellular GSSG, achieved through delivery of GSSG into cells by a liposome delivery method, produced significant protein *S*-glutathionylation and similar microtubule depolymerization in NCI-H226 cells as observed in this investigation (unpublished data from this laboratory). Taken together, we believe that microtubule *S*-glutathionylation causes microtubule depolymerization. The malfunction of microtubules led to cell morphological changes, cell cycle arrest at G~2~/M phase, and eventually apoptosis.

Finally, the cancer growth inhibition effects of 2-AAPA against other human cancer cell lines were determined. The IC~50~ determination reveals that 2-AAPA inhibited these cell lines with similar IC~50~ values which are close to the concentrations that affect microtubule function suggesting that microtubule *S*-glutathionylation is likely the contribution to cancer cell growth inhibition.

Conclusions
===========

In summary, our investigation provides evidence demonstrating that microtubule *S*-glutathionylation will lead to microtubule depolymerization, cell cycle arrest at G~2~/M phase, and apoptosis. This mechanism of action is different than those of currently used antimitotic agents. This finding suggests that microtubule *S*-glutathionylation can be potentially used as a novel approach to develop new classes of antimitotic agents which can be complimentary to the existing antimitotic agents.
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